The University of Birmingham has received its first Wellcome Leap award as part of a new £48m (US$60m) ‘Dynamic Resilience’ programme to fund researchers investigating ways to improve health in later life.
Dr Thomas Jackson from the Institute of Inflammation and Ageing at The University of Birmingham has been awarded a multi-million-pound contract to research the responses of older people undergoing a stressful health event – an operation for colorectal cancer.
He will lead a multidisciplinary team of researchers from the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust, King’s College London, and Guys and St Thomas’s NHS Foundation Trust. The team will study biological signals (biomarkers) to see if they are able to predict who will recover well after surgery (i.e., are resilient) and who may need additional help.
They will also test whether some existing drugs and supplements might be able to improve health in older volunteers.
Dr Jackson said: “It is exciting to be a part of the Wellcome Leap Dynamic Resilience programme, securing funding for important clinical research in geriatric medicine that will expand our knowledge and underpin larger-scale trials. With advances in our understanding of ageing, we can identify different underlying biological mechanisms associated with multiple different conditions including frailty and delirium.
“Our team, which includes specialists in inflammation and ageing, computational biology, and psychology, along with our external partners, will look at existing drugs and explore how they might target key biological mechanisms relevant across conditions that are common in frail, older populations.
”Dynamic Resilience is funded jointly by Wellcome Leap and Temasek Trust. The 14 successful applicants are The Aga Khan University, Kenya, BioAge Labs, Inc., Centenary Institute/University of Technology Sydney, Karolinska Institutet, King’s College London, Loughborough University, National University Health System, National University of Singapore, NMI Natural and Medical Sciences Institute at the University of Tübingen, RIKEN, Universidad de Chile, University of California San Diego, and University of Oslo.
